King's College London

Research portal

PR3-ANCA: A promising biomarker for ulcerative colitis with extensive disease

Research output: Contribution to journalArticlepeer-review

Michael Mahler, Dimitrios P. Bogdanos, Polychronis Pavlidis, Marvin J. Fritzler, Elena Csernok, Jan Damoiseaux, Chelsea Bentow, Zakera Shums, Alastair Forbes, Gary L. Norman

Original languageEnglish
Pages (from-to)267-273
Number of pages7
JournalClinica Chimica Acta
Published23 Sep 2013

King's Authors


Background: We determined if PR3-ANCA is a biomarker that differentiates ulcerative colitis (UC) from Crohn's disease (CrD). Methods: A total of 946 sera were tested, including 86 granulomatosis with polyangiitis (GPA) and 491 inflammatory bowel disease (IBD) patients (283 UC and 208 CrD), 264 pathological controls (various diseases) and 105 healthy individuals. All samples were tested for PR3-ANCA by ELISA (QUANTA Flash Lite®, INOVA Diagnostics) and chemiluminescent immunoassays (CIA QUANTA Flash PR3). Conventional anti-neutrophil cytoplasmic antibody (ANCA) indirect immunofluorescence assays (IIF) was performed with NOVA Lite™ (INOVA Diagnostics). Results: PR3-ANCA by CIA were detected in 31.1% UC vs. 1.9% CrD sera (p=. 2.2E. -. 16), and by ELISA in 6% UC and 0% CrD (p=. 0.0003). In GPA patients, PR3-ANCA were detected in 75.6% by CIA and 61.6% by ELISA (p

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454